NT-I7

Phase 1Small molecule

WWashington University School of Medicine

NT-I7 is one of 212 small molecule programs targeting Glioma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

211

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

LymphomaActive, not recruiting

Skin CancerActive, not recruiting

Esophageal AdenocarcinomaActive, not recruiting

Multiple MyelomaActive, not recruiting

COVID-19Active, not recruiting

Progressive Multifocal LeukoencephalopathyActive, not recruiting

GliomaPhase 1

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Skin CancerPhase 1/Phase 2

Active, not recruiting

Esophageal AdenocarcinomaPhase 1

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

COVID-19Phase 1

Active, not recruiting

Progressive Multifocal LeukoencephalopathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Preclinical

2 2

Singulair

AstraZeneca

Preclinical

1 3

NT-I7

WWashington University School of Medicine

Phase 1

1 4

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 6

Nitrostat

VViatris Specialty LLC

Preclinical

1 7

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

3 8

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 9

Tpa

UUniversity of Florida

Preclinical

1 10

Disease-Modifying Anti-Rheumatic Drugs

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Lymphoma

NCT07052305

Q4 2028

Phase 1Not yet recruiting

Multiple Myeloma

NCT07200089

Clinical

Trials by Indication[1]

COVID-191 trial

Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)

Withdrawn·WWashington University School of Medicine·Phase 1·NCT04498325

Esophageal Adenocarcinoma1 trial

NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma

Terminated·NNeoImmuneTech·Phase 1·NCT04594811·10 enrolled

Progressive Multifocal Leukoencephalopathy1 trial

NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT04781309·12 enrolled

Advanced Solid Tumors1 trial

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Completed·NNeoImmuneTech·Phase 1/2·NCT04332653·215 enrolled

Skin Cancer1 trial

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Terminated·NNeoImmuneTech·Phase 1/2·NCT03901573·31 enrolled

3 more indications

Multiple Myeloma1 trial

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

Not yet recruiting·WWashington University School of Medicine·Phase 1·NCT07200089·40 enrolled

Lymphoma1 trial

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Recruiting·WWashington University School of Medicine·Phase 1·NCT07052305·24 enrolled

Glioma1 trial

Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02659800·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for NT-I7. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NT-I7 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NT-I7. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: WWashington University School of Medicine

NT-I7

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Trials by Indication[1]

COVID-191 trial

Esophageal Adenocarcinoma1 trial

Progressive Multifocal Leukoencephalopathy1 trial

Advanced Solid Tumors1 trial

Skin Cancer1 trial

Multiple Myeloma1 trial

Lymphoma1 trial

Glioma1 trial

References

Drug Info

Quick Facts

Related News